Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Erythropoietin for Asphyxia and Encephalopathy
NCT02811263Phase 3Completed
- Sponsor
- University of California, San Francisco
- Start
- Jan 2017
- Primary completion
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of erythropoietin in hypoxic-ischemic encephalopathy (HIE), sponsored by University of California, San Francisco. Started Jan 2017; status: completed.
02
Drugs
erythropoietin
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on NCT02811263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02811263.